Literature DB >> 8083581

Renal cysts in transgenic mice expressing transforming growth factor-alpha.

D A Lowden1, G W Lindemann, G Merlino, B D Barash, J P Calvet, V H Gattone.   

Abstract

Transforming growth factor-alpha (TGF-alpha) is a member of the epidermal growth factor (EGF) family of proteins and, like EGF, elicits its cellular function by binding to the EGF receptor. EGF stimulation may have a role in several normal and pathologic processes in the kidney, and EGF has been implicated in the development of renal cysts in vitro and in human autosomal dominant polycystic kidney disease. We sought to determine whether renal expression of an EGF-like protein (TGF-alpha) could lead to the formation of renal cysts in vivo. We examined morphologic alterations to the normal kidney caused by renal expression of a TGF-alpha transgene linked to a mouse metallothionein promoter stably integrated into the genome of the CD1 mouse. TGF-alpha transgene expression was induced with exogenous zinc treatment starting at 4 weeks of age, and mice were killed at 8 weeks of age. The transgene was expressed at higher levels in female transgenic mice than in male transgenic mice. The augmented expression of the TGF-alpha transgene in females was associated with increased renal size and the development of renal epithelial cysts. Both male and female mice exhibited increases in glomerular size and mesangial volume density. These results provide evidence that stimulation by an endogenous EGF-like protein can lead to renal enlargement, glomerular mesangial expansion, and renal cyst formation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8083581

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  17 in total

1.  TGF-alpha mediates genetic susceptibility to chronic kidney disease.

Authors:  Denise Laouari; Martine Burtin; Aurélie Phelep; Carla Martino; Evangeline Pillebout; Xavier Montagutelli; Gérard Friedlander; Fabiola Terzi
Journal:  J Am Soc Nephrol       Date:  2010-12-23       Impact factor: 10.121

2.  A new in vitro bioassay for cyst formation by renal cells from an autosomal dominant rat model of polycystic kidney disease.

Authors:  R Pey; J Bach; G Schieren; N Gretz; M Hafner
Journal:  In Vitro Cell Dev Biol Anim       Date:  1999 Nov-Dec       Impact factor: 2.416

3.  Epidermal growth factor receptor activity mediates renal cyst formation in polycystic kidney disease.

Authors:  W G Richards; W E Sweeney; B K Yoder; J E Wilkinson; R P Woychik; E D Avner
Journal:  J Clin Invest       Date:  1998-03-01       Impact factor: 14.808

4.  Targeted expression of a dominant-negative EGF-R in the kidney reduces tubulo-interstitial lesions after renal injury.

Authors:  F Terzi; M Burtin; M Hekmati; P Federici; G Grimber; P Briand; G Friedlander
Journal:  J Clin Invest       Date:  2000-07       Impact factor: 14.808

5.  Transforming growth factor alpha (TGF-alpha) and other targets of tumor necrosis factor-alpha converting enzyme (TACE) in murine polycystic kidney disease.

Authors:  Raghad Nemo; Noel Murcia; Katherine Macrae Dell
Journal:  Pediatr Res       Date:  2005-03-17       Impact factor: 3.756

Review 6.  The VHL tumor suppressor in development and disease: functional studies in mice by conditional gene targeting.

Authors:  Volker H Haase
Journal:  Semin Cell Dev Biol       Date:  2005-04-26       Impact factor: 7.727

7.  JunD protects against chronic kidney disease by regulating paracrine mitogens.

Authors:  Evangéline Pillebout; Jonathan B Weitzman; Martine Burtin; Carla Martino; Pierre Federici; Moshe Yaniv; Gérard Friedlander; Fabiola Terzi
Journal:  J Clin Invest       Date:  2003-09       Impact factor: 14.808

8.  Acceleration of polycystic kidney disease progression in cpk mice carrying a deletion in the homeodomain protein Cux1.

Authors:  Neal I Alcalay; Madhulika Sharma; Dianne Vassmer; Brandon Chapman; Binu Paul; Jing Zhou; Jennifer G Brantley; Darren P Wallace; Robin L Maser; Gregory B Vanden Heuvel
Journal:  Am J Physiol Renal Physiol       Date:  2008-10-01

9.  Urinary EGF Receptor Ligand Excretion in Patients with Autosomal Dominant Polycystic Kidney Disease and Response to Tolvaptan.

Authors:  Laura R Harskamp; Ron T Gansevoort; Wendy E Boertien; Wim van Oeveren; Gerwin E Engels; Harry van Goor; Esther Meijer
Journal:  Clin J Am Soc Nephrol       Date:  2015-07-31       Impact factor: 8.237

Review 10.  Polycystic kidney diseases: from molecular discoveries to targeted therapeutic strategies.

Authors:  O Ibraghimov-Beskrovnaya; N Bukanov
Journal:  Cell Mol Life Sci       Date:  2008-02       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.